TREATMENT OF CHILDHOOD SOCIAL PHOBIA

描述(改编自申请者摘要)：社交恐惧症影响3%-5% 儿童患病率随着年龄的增长而上升。患有社交恐惧症的青少年 公开演讲、公开阅读或公开写作、参加聚会、互动 与权威人士，使用公共厕所，并与非正式互动 其他。临床相关因素包括头痛或胃痛、恐慌、 回避，普遍焦虑，烦躁不安，孤独和非常有限的范围 关于社会关系的。在极端情况下，拒绝上学或其他行为 问题随之而来。社会发展所需的社交技能不足 是很常见的。其他疾病经常并存，最常见的是广泛性焦虑 精神障碍、分离焦虑症和特定的恐惧症。几乎没有几个 对这种衰弱、慢性和高度流行的疾病的治疗研究。 最近的研究结果表明，一种新的心理社会治疗(社会有效性 儿童疗法；SET-C)对8-11岁有效，导致减少 情绪困扰和社会功能的改善。治疗效果一直很好 维护时间长达6个月。因为社交恐惧症的流行 随着年龄的增长，至少在青春期，对青少年的治疗是 需要的。这里提出的研究将是一项两个地点的研究，扩展了对 将-C设置为更大的样本，并将年龄范围扩展到15岁。因为 现有数据表明氟西汀是一种很有前途的药理活性物质。 治疗后，将SET-C与氟西汀进行双盲随机对照研究 安慰剂对照设计。氟西汀尚未与服用安慰剂的药片进行比较 对照设计使用了一个具有代表性的儿童社交恐惧症样本。 因此，这项研究将允许继续评估SET-C的疗效 扩大了年龄范围，并与氟西汀进行了比较。此外，这项研究将 提供氟西汀与安慰剂比较的疗效数据。最后， 治疗的持久性将在一年的随访期内进行监测。这个 样本将足够大，以提供临床上的信心 调查结果的意义以及进行初步研究审查 治疗临床医生的预测者和调节者。同样，关键数据在 氟西汀的疗效将会显现。

DESCRIPTION (Adapted from the Applicant's Abstract): Social phobia affects 3-5% of children, and prevalence rises with age. Youth with social phobia fear public speaking, reading or writing in public, going to parties, interacting with authority figures, using public restrooms and interacting informally with others. Clinical correlates include headaches or stomachaches, panic, avoidance, general anxiety, dysphoria, loneliness, and a very restricted range of social relationships. In extreme cases, school refusal or other behavior problems result. Deficiencies in social skills necessary for social development are common. Other disorders frequently co-occur, most often generalized anxiety disorder, separation anxiety disorder, and specific phobia. There are few treatment studies of this debilitating, chronic, and highly prevalent disorder. Recent findings indicate a new psychosocial treatment (Social Effectiveness Therapy for Children; SET-C) is efficacious for ages 8-11, resulting in reduced emotional distress and improved social functioning. Treatment effects have been maintained for up to 6 months. Because the prevalence of social phobia increases with age at least through adolescence, treatments for adolescents are needed. The study proposed here will be a two-site study extending the study of SET-C to a larger sample, and extending the age range to age 15. Because available data suggest that fluoxetine is a promising pharmacological treatment, SET-C will be compared to fluoxetine in a double-blind randomized placebo control design. Fluoxetine has yet to be compared to pill placebo in a controlled design using a representative sample of childhood social phobics. Thus, the study will allow continued evaluation of SET-C's efficacy using an expanded age range, and comparing it to fluoxetine. Furthermore, the study will provide data on the efficacy of fluoxetine compared to pill placebo. Finally, durability of treatment will be monitored over a 1-year follow-up period. The sample will be sufficiently large to provide confidence in the clinical meaningfulness of the findings and to conduct initial studies examining predictors and moderators of treatment clinicians. Similarly, critical data on the efficacy of fluoxetine will be available.